Women's Reproductive Cancers

The gynecologic oncologists at the Cedars-Sinai Center for Women's Reproductive Cancers practice leading-edge, comprehensive, clinical cancer care.

All of the center's physicians are highly skilled in advanced laparoscopic procedures. They offer patients the ability to manage reproductive cancers using minimally invasive surgical procedures. Additionally, the center's physicians are trained in the use of the da Vinci advanced robotic system to treat these diseases.

In the clinic, we apply the most up-to-date treatment regimens, including intraperitoneal chemotherapy and targeted biologic therapeutics.

Research to uncover new and better approaches to treating women's reproductive cancers are a key component of the work at the center. A large number of clinical trials are underway at the center. Physicians and researchers at the center participate in national and international studies including collaborations with the National Cancer Institute's Gynecologic Oncology Group. These efforts bring to our patients relevant, effective, and cutting edge treatments to manage their gynecologic cancers.

Our physicians have expertise in all gynecologic malignancies, including advanced and recurrent ovarian cancers, hereditary gynecologic cancers and fertility-sparing surgery.

Measuring Quality of Care at the Cedars-Sinai Center for Women's Reproductive Cancer

At the Cedars-Sinai Center for Women's Reproductive Cancer, a variety of factors are monitored to measure the quality of care available to patients, including:

  • Patient and procedure volumes
  • Number of clinical trials
  • Average length of stay

These factors are explained in more detail below. Additional information is provided about five-year survival rates for women with ovarian cancer treated at Cedars-Sinai and at hospitals across the nation and state.

Patient Volume at the Cedars-Sinai Center for Women's Reproductive Cancer

Cedars-Sinai ranks fifth nationally and first locally among the busiest gynecologic oncology surgical services.

Over the past three years, the Cedars-Sinai Center for Women's Reproductive Cancers continues to see a high volume of new and returning patients.  

Cedars-Sinai Women's Reproductive Cancers Center of Excellence 2013 2014 2015
Number of new patient visits 1,192 1,301 954
Number of returning patient visits (with MDs; excludes visits with nurses and other allied health professionals) 5,155 9,364* 4,158

*data for 2014 also includes post-op visits

Clinical Trials at the Cedars-Sinai Women's Reproductive Cancers Center of Excellence

Clinical trials are used to evaluate the effectiveness and safety of medications, treatments or medical devices by monitoring their effects on large groups of people. Cedars-Sinai is committed to ongoing research to discover new and more effective treatments.

The tissue bank at the Cedars-Sinai Women's Reproductive Cancers Center of Excellence collects, preserves and studies tissue samples as part of its ongoing research efforts to find new and better treatments for women's reproductive cancers.

Cedars-Sinai Women's Reproductive Cancers Center of Excellence 2013 2014 2015
Number of clinical trials 4 6 5
Number of patients enrolling in tissue banking 237 254 518


Inpatient Procedure Volumes and Average Length of Stay for Patients at the Cedars-Sinai Women's Reproductive Cancers Center of Excellence

Studies suggest that for many surgical procedures, hospitals that perform high volumes have better quality outcomes, i.e. lower short-term and long-term mortality and morbidity. Volume is an indicator of experience, which influences outcomes in multiple ways.

In addition to the experience of surgeons in performing specific procedures, high volume hospitals may institute specific care processes that improve out comes and the infrastructure dedicated to particular clinical specialties, including related technology and intensive care personnel. Commitment to quality standards throughout the institution is also an important determinant of better outcomes.1,2 In addition, outcomes for high-risk procedures have been shown to be better when performed by more highly trained surgeons than by general surgeons.3

Average length of stay is another aspect of quality of patient care that is monitored at Cedars-Sinai. This refers to the average number of days a patient stays at Cedars-Sinai after being admitted. The goal is to ensure that all patients are appropriately treated in the hospital for their respective conditions, and are not hospitalized longer than they need to be. 

Procedure Volumes and Average Length of Stay at the Cedars-Sinai Women's Reproductive Cancers Center 2015* Volume of Procedures Average Length of Stay (In Days) Expected
Uterine and endometrial procedures
     January - September 438 2.4 2.6
     October - December 153 2.8 3.1
Ovarian and fallopian tube procedures
     January - September 138 3.4 3.9
     October - December 34 2.9 3.1
Cervical and endocervical procedures
     January - September 25 2.0 3.2
     October - December 11 2.2 3.1
Vulva procedures
     January - September 9 2.3 3.2
     October - December 14 2.5 3.0
Total 822 --  

*The data comes from the University HealthSystem Consortium (UHC), an alliance of more than 300 of the nation’s non-profit academic medical centers and their affiliated hospitals. The majority of these facilities participate in UHC's Clinical DataBase/Resource Manager. Effective for all discharges as of Oct. 1, 2015, the U.S. Department of Health and Human Services (HHS) mandated that any entity covered by the Health Insurance Portability and Accountability Act (HIPAA) switch from ICD-9 to ICD-10 for medical coding. The new code set provides a significant increase in the specificity of the reporting, allowing more information to be conveyed in a code. In order to ensure accurate comparisons of observed to expected for Length of Stay and Mortality measures, data is reported separately for those cases coded with ICD-9 (January – September 2015) vs. those coded using ICD-10 (October-December 2015). The data for January-September 2015 discharges was accessed on February 15, 2015 and the data for October-December discharges was accessed on March 14, 2016.

1Bach PB, Ann Intern Med 2009; 150:729-30

2Greene FL, Ann Surg Oncol 2007; 15:14-15

3Kozower BD et al, Ann Thorac Surg 2009; 86:1405-08